Salud financiera de hoja de balance de H. Lundbeck

Salud financiera controles de criterios 5/6

H. Lundbeck tiene un patrimonio de accionistas total de DKK22.0B y una deuda total de DKK3.7B, lo que sitúa su ratio deuda-patrimonio en 16.8%. Sus activos y pasivos totales son DKK37.4B y DKK15.4B respectivamente. El BAIT de H. Lundbeck es de DKK3.3B, por lo que su ratio de cobertura de intereses es de -102. Tiene efectivo e inversiones a corto plazo que ascienden a DKK5.0B.

Información clave

16.6%

Ratio deuda-patrimonio

kr.3.72b

Deuda

Ratio de cobertura de intereses	-23x
Efectivo	kr.5.11b
Patrimonio	kr.22.44b
Total pasivo	kr.15.42b
Activos totales	kr.37.85b

Actualizaciones recientes sobre salud financiera

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

Jun 05

Recent updates

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

Jun 05

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

Mar 07

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Feb 22

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Feb 10

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (DKK13.3B) de HLUN B superan a sus pasivos a corto plazo (DKK8.0B).

Pasivo a largo plazo: Los activos a corto plazo de HLUN B (DKK13.3B) superan a sus pasivos a largo plazo (DKK7.4B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: HLUN B tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de HLUN B ha crecido de 0.5% a 16.8% en los últimos 5 años.

Cobertura de la deuda: La deuda de HLUN B está bien cubierta por el flujo de caja operativo (109.9%).

Cobertura de intereses: HLUN B gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.

Salud financiera de hoja de balance de H. Lundbeck

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

Recent updates

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Key Executive recently bought kr.751k worth of stock

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera